References
- van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infections. A review of the world literature. Helicobacter 1996;1:6–19.
- Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102:493–6.
- Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88:505–9.
- Graham DY, de Boer WA, Tytgat GNJ. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072–6.
- Williamson R, Pipkin GA, Dixon JS, Wood JR. Approaches to the prevention and treatment of Helicobacter pylori infection. Yale J Biol Med 1997;70:7–18.
- Lerang F, Moum B, Ragnhildstveit E. A comparison between omeprazole-based triple therapy and bismuth based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Int J Gastroenterol 1997;92: 1–6.
- Berstad A, Hatlebakk JG, Wilhelmsen I. Follow-up on 242 patients with peptic ulcer disease one year after eradication of Helicobacter pylori infection. Hepat Gastroenterol 1995;42: 655–9.
- Marshall BJ. The use of bismuth in gastroenterology. Am J Gastroenterol 1991;86:16–23.
- Slikkerveer A, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adv Drug Exp 1989;4:303–23.
- Tillman LA, Drake FM, Dixon JS, Wood JR. Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol Ther 1996;10:459–67.
- Berstad A, Olafsson S, Tefera S, Berstad K, Hundal Ø, Bergseth M, et al. Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. J Physiol Pharmacol 1996;47:31–49.
- Rabasseda X, Mealy N, Castañer J. Ranitidine bismuth citrate. Drugs Future 1995;20:480–2.
- Sun H, Li H, Sadler PJ. The biological and medicinal chemistry of bismuth. Chem Ber 1997;130:669–81.
- Dittes V, Vogel E, Keppler BK. Overview on bismuth(III) and bismuth(V) complex with activity against Helicobacter pylori. Coord Chem Rev 1997;163:345–64.
- Gløgård C, Dahlgren A, Aasen AJ, Klaveness J, Berdal B, Bergan T. Synthesis and antimicrobial activity of organic bismuth compounds. Int Agents J Antibiot Agents. In press.
- Meyers AI, Temple DL, Haidukewych D, Mihelich ED. Oxazolines. XI. Synthesis of functionalized aromatic and aliphatic acids. A useful protecting group for carboxylic acids against Grignard and hydride reagents. J Org Chem 1974;39:2787–93.
- de Ketelaere RF, Delbeke FT, van der Kelen GP. Organo group VB chemistry. III. Synthesis and NMR spectra of some tertiary substituted arylstibines and arylbismuthines. J Organomet Chem 1971;30:365–8.
- Matano Y, Kinoshita M, Suzuki H. Synthesis and reactions of some crowded triorganylbismuthines. Bull Chem Soc Jpn 1992; 65:3504–6.
- Challenger F. XXVIII. Organo-derivatives of bismuth. J Chem Soc 1916;109:250–1.
- Challenger F, Wilkinson JF. XVI. Organo-derivatives of bismuth. Part V. The stability of halogen, cyano- and thiocyanoderivatives of tertiary aromatic bismuthines. J Chem Soc 1922;121:91–104.
- Stablers R, Campbell CJ, Clayton NM, Clitherow JW, Grinham CJ, Mc Colm AA, et al. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther 1993;7:237–46.
- Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pyloric infection. Aliment Pharmacol Ther 1997;11 Suppl 1:27–33.